The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA. Ardelyx focuses on small molecules to treat diseases with significant unmet medical needs. The company’s only approved drug is Isbrela (tenapanor), approved to treat irritable bowel syndrome (IBS) with constipation. However, the company is looking to add indications to tenapanor. A different version of the drug, called Xphozah, is looking to be approved to control serum phosphate levels in adults with CKD on dialysis or those who have had a poor response or intolerance to phosphate binder therapy. Xphozah has a Prescription Drug User Fee Act (PDUFA) date of Oct. 17 for Food and Drug Administration (FDA) approval.
- It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.
- Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.
To see all exchange delays and terms of use please see Barchart’s disclaimer. Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment. Yigal Nochomovitz’s rating for Ardelyx’s stock is based on a number of critical factors. He predicts a greater than 95% probability for the approval of Ardelyx’s drug, Xphozah, designed for hyperphosphatemia patients on dialysis. This optimism stems from the positive Advisory Committee (AdCom) feedback last November and the Office of New Drugs’ (OND) unusual approval of Ardelyx’s appeal to the initial Complete Response Letter (CRL). Nochomovitz believes this indicates the drug’s approval is almost certain, with label negotiation being the only significant remaining hurdle.
Should You Buy Ardelyx Inc (ARDX) Stock Friday Morning?
So they generally do consider buying larger companies that are included in the relevant benchmark index. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Nochomovitz covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Coherus Biosciences, and Atara Biotherapeutics. According to TipRanks, Nochomovitz has an average return of 4.1% and a 39.37% success rate on recommended stocks. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC.
- The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
- It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.
- The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.
- However, the company is looking to add indications to tenapanor.
- 6 brokerages have issued twelve-month price targets for Ardelyx’s shares.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets.
Health Care Stocks Whale Activity In Today’s Session
A closer look at our ownership figures suggests that the top 23 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. Let’s take a closer look to see what the different types of shareholders can tell us about Ardelyx. You have already added five stocks to your watchlist.
the Ardelyx Inc Stock Price Forecast & Prognosis
Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year. These returns cover a period from January 1, 1988 through September 4, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
Upgrade to MarketBeat All Access to add more stocks to your watchlist. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd vintage fx 2023. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.
XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. review: more money than god: hedge funds and the making of a new elite The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Ardelyx Stock Forecast, «ARDX» Share Price Prediction Charts
Ardelyx Inc. shares soared more than 60% in after-hours trading Wednesday, after the company reported positive results for a study of a proposed drug. Ardelyx said a second Phase 3 study of tenapanor, a drug targeting irr… Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.
Ardelyx’s (NASDAQ:ARDX) Kidney Disease Therapy Bags Approval in Japan
The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Plus, ARDX info will be updated daily in your Zacks.com Portfolio Tracker – also free.
The company said it would launch the drug in the fourth quarter, pending approval. Ardelyx also has a pipeline candidate, RDX013, that is in phase 2 trials to lower potassium levels to treat CKD. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer.
ARDX Valuation Summary
The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company’s product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control activ trades review of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
